Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CANadian Effectiveness of UPadacitinib in Adult Moderate-to-severe aTopIc derMatitis Patients Who Are Inadequate Responders to Dupilumab or diScontinuing Dupilumab Due to safEty/Tolerability Reasons: The CAN UpTIMISE Study

NCT05394792 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05394792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CANadian Effectiveness of UPadacitinib in Adult Moderate-to-severe aTopIc derMatitis Patients Who Are Inadequate Responders to Dupilumab or diScontinuing Dupilumab Due to safEty/Tolerability Reasons: The CAN UpTIMISE Study
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
June 1, 2022
Completion date
August 15, 2024
Enrollment
111 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis